http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Bioventus Reports Third Quarter Financial Results
-
Bitcoin Bancorp Partners with Sailo Technologies to Launch Revolutionary Bitcoin Treasury Management Platform Amid Surge in Corporate Adoption
-
QOL Medical to acquire Evoke Pharma for $11 per share in cash
-
GENPREX receives European patent intent for cancer gene therapy combination
-
Magnet Biomedicine Appoints Bharat Reddy, Ph.D., as Chief Business Officer
-
Zoetis Announces Third Quarter 2025 Results
-
Evoke Pharma Enters into Definitive Agreement to Be Acquired by QOL Medical
-
Compass, Inc. Reports Record Third Quarter 2025 Results
-
Nature Communications Study Supports HER2DX as a Genomic Tool for Tailored Therapy in Older Individuals With HER2+ Breast Cancer
-
Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
-
GreyNoise Integrates with CrowdStrike Falcon Next-Gen SIEM to Unify Network Intelligence and Accelerate SOC Transformation
-
Hagerty Reports Third Quarter 2025 Results; Increases 2025 Outlook
-
Merck receives $700 million from Blackstone for cancer drug development
-
Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)
-
BD Achieves Milestone in AGILITY Study of Revello™ Vascular Covered Stent for Treatment of Peripheral Artery Disease
-
Merck assumes full rights to MK-8690 drug after $150 million Falk deal
-
Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody
-
Descartes’ Study Finds 67% of Freight Forwarders and Customs Brokers View Technology as Fundamental to Growth
-
Denison Mines faces judicial review over Wheeler River uranium project
-
Denison Acknowledges Application for Judicial Review Regarding Provincial Environmental Assessment Approval for Wheeler River
-
22nd Century Group Reports Third Quarter 2025 Financial Results
-
BROAD ARROW’S INAUGURAL ZÜRICH AUCTION ACHIEVES OVER CHF 22M WITH 87 PERCENT SELL-THROUGH RATE
-
Breakthrough in 5G FWA to Bring High-Speed Broadband to MDUs
-
SnapLogic Accelerates Enterprise AI Adoption with New Capabilities for Agents, MCP, and Enhanced AI Governance
-
SnapLogic Eliminates Legacy Migration Costs by up to 80% with SnapLogic Intelligent Modernizer
-
Bitget Launches Institutional Financing Program Offering Interest-Free 2M USDT to Boost Altcoin Liquidity
-
Golden Cariboo Resources Commences Autumn Drill Campaign at the Quesnelle Gold Quartz Mine Property
-
Star Copper Kicks Off Inaugural Drilling at Star North Target
-
DMG Blockchain Solutions Announces Asset Purchase to Establish its First US-based Data Center, October Preliminary Operational Results
-
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
-
Best Meme Coins to Buy Today: MoonBull Presale Taps $550K, SHIB Gains FTSE Grayscale Recognition, DOGE Price Pulls Back
-
New York seeks dismissal of lawsuit by Elon Musk's X over hate speech law
-
Christopher J.L. Murray Receives 2025 James and Sarah Fries Prize for Improving Health
-
HII appoints Tim Taylor as VP of engineering at Newport News Shipbuilding
-
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
-
HII Names Tim Taylor as Vice President of Engineering, Technology, and Design at Newport News Shipbuilding
-
BlackSky to Participate at Three Upcoming Investor Conferences
-
Best Crypto Coins to Invest In: Bitcoin Price Dips 3.2%, BNB Approaches $1,200 Breakout, MoonBull Presale Surpasses $550K
-
Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing
-
NANOBIOTIX to Participate in Investor Conferences the Week of November 10th
-
Hagerty Announces New Partnership with Liberty Mutual
-
Upwork Reports Third Quarter 2025 Financial Results
-
Calamos Investments Closed-End Funds (NASDAQ: CHI, CHY, CSQ, CGO, CHW, CCD and CPZ) Announce Monthly Distributions and Required Notifications of Sources of Distribution
-
NurExone Accepted into ARMI’s BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing
-
Veradigm appoints Tehsin Syed as chief product and technology officer
-
Veradigm Appoints Tehsin Syed as Chief Product and Technology Officer
-
Mdxhealth to Release Third Quarter 2025 Financial Results on November 12
-
HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS
-
UCB gains FDA approval for first TK2 deficiency treatment KYGEVVI
-
U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

